<SEC-DOCUMENT>0000905148-25-000308.txt : 20250131
<SEC-HEADER>0000905148-25-000308.hdr.sgml : 20250131
<ACCEPTANCE-DATETIME>20250131191850
ACCESSION NUMBER:		0000905148-25-000308
CONFORMED SUBMISSION TYPE:	SCHEDULE 13D/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250131
DATE AS OF CHANGE:		20250131

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BridgeBio Pharma, Inc.
		CENTRAL INDEX KEY:			0001743881
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-91059
		FILM NUMBER:		25580036

	BUSINESS ADDRESS:	
		STREET 1:		3160 PORTER DR.
		STREET 2:		SUITE 250
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94304
		BUSINESS PHONE:		(650) 391-9740

	MAIL ADDRESS:	
		STREET 1:		3160 PORTER DR.
		STREET 2:		SUITE 250
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94304

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BridgeBio Pharma LLC
		DATE OF NAME CHANGE:	20180618

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			VIKING GLOBAL INVESTORS LP
		CENTRAL INDEX KEY:			0001103804
		ORGANIZATION NAME:           	
		IRS NUMBER:				134055118
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A

	BUSINESS ADDRESS:	
		STREET 1:		600 WASHINGTON BLVD.
		STREET 2:		FLOOR 11
		CITY:			STAMFORD
		STATE:			CT
		ZIP:			06901
		BUSINESS PHONE:		212-672-7050

	MAIL ADDRESS:	
		STREET 1:		600 WASHINGTON BLVD.
		STREET 2:		FLOOR 11
		CITY:			STAMFORD
		STATE:			CT
		ZIP:			06901
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13D/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13D" xmlns:com="http://www.sec.gov/edgar/common">
<headerData>
<submissionType>SCHEDULE 13D/A</submissionType>
<previousAccessionNumber>0000903423-19-000277</previousAccessionNumber>
<filerInfo>
<filer>
<filerCredentials>
<cik>0001103804</cik>
<ccc>XXXXXXXX</ccc>
</filerCredentials>
</filer>
<liveTestFlag>LIVE</liveTestFlag>



</filerInfo>
</headerData>
<formData>
<coverPageHeader>
<amendmentNo>5</amendmentNo>
<securitiesClassTitle>Common Stock, par value $0.001 per share</securitiesClassTitle>
<dateOfEvent>01/31/2025</dateOfEvent>
<previouslyFiledFlag>false</previouslyFiledFlag>
<issuerInfo>
<issuerCIK>0001743881</issuerCIK>
<issuerCUSIP>10806X102</issuerCUSIP>
<issuerName>BridgeBio Pharma, Inc.</issuerName>
<address>
<com:street1>3160 Porter Drive</com:street1>
<com:street2>Suite 250</com:street2>
<com:city>Palo Alto</com:city>
<com:stateOrCountry>CA</com:stateOrCountry>
<com:zipCode>94304</com:zipCode>
</address>
</issuerInfo>
<authorizedPersons>
<notificationInfo>
<personName>Matthew Bloom</personName>
<personPhoneNum>(212) 672-7059</personPhoneNum>
<personAddress>
<com:street1>General Counsel and CCO</com:street1>
<com:street2>600 Washington Boulevard, Floor 11</com:street2>
<com:city>Stamford</com:city>
<com:stateOrCountry>CT</com:stateOrCountry>
<com:zipCode>06901</com:zipCode>
</personAddress>
</notificationInfo>
</authorizedPersons>
</coverPageHeader>
<reportingPersons>
<reportingPersonInfo>
<reportingPersonCIK>0001103804</reportingPersonCIK>
<reportingPersonName>VIKING GLOBAL INVESTORS LP</reportingPersonName>
<memberOfGroup>b</memberOfGroup>
<fundType>OO</fundType>
<citizenshipOrOrganization>DE</citizenshipOrOrganization>
<soleVotingPower>0</soleVotingPower>
<sharedVotingPower>22055375</sharedVotingPower>
<soleDispositivePower>0</soleDispositivePower>
<sharedDispositivePower>22055375</sharedDispositivePower>
<aggregateAmountOwned>22055375</aggregateAmountOwned>
<isAggregateExcludeShares>N</isAggregateExcludeShares>
<percentOfClass>11.7</percentOfClass>
<typeOfReportingPerson>PN</typeOfReportingPerson>
<commentContent>All share percentage calculations in this Amendment No. 5 to the Schedule 13D are based on 188,989,802 shares of Common Stock, par value $0.001 per share, of BridgeBio Pharma, Inc. (the "Issuer") outstanding as of November 5, 2024, as reported in the Issuer's quarterly report on Form 10-Q filed with the Securities and Exchange Commission (the "Commission") on November 12, 2024.</commentContent>
</reportingPersonInfo>
<reportingPersonInfo>
<reportingPersonCIK>0001132625</reportingPersonCIK>
<reportingPersonName>VIKING GLOBAL PERFORMANCE LLC</reportingPersonName>
<memberOfGroup>b</memberOfGroup>
<fundType>OO</fundType>
<citizenshipOrOrganization>DE</citizenshipOrOrganization>
<soleVotingPower>0</soleVotingPower>
<sharedVotingPower>487901</sharedVotingPower>
<soleDispositivePower>0</soleDispositivePower>
<sharedDispositivePower>487901</sharedDispositivePower>
<aggregateAmountOwned>487901</aggregateAmountOwned>
<isAggregateExcludeShares>N</isAggregateExcludeShares>
<percentOfClass>0.3</percentOfClass>
<typeOfReportingPerson>OO</typeOfReportingPerson>
</reportingPersonInfo>
<reportingPersonInfo>
<reportingPersonCIK>0001759530</reportingPersonCIK>
<reportingPersonName>Viking Global Equities Master Ltd.</reportingPersonName>
<memberOfGroup>b</memberOfGroup>
<fundType>OO</fundType>
<citizenshipOrOrganization>E9</citizenshipOrOrganization>
<soleVotingPower>0</soleVotingPower>
<sharedVotingPower>487901</sharedVotingPower>
<soleDispositivePower>0</soleDispositivePower>
<sharedDispositivePower>487901</sharedDispositivePower>
<aggregateAmountOwned>487901</aggregateAmountOwned>
<isAggregateExcludeShares>N</isAggregateExcludeShares>
<percentOfClass>0.3</percentOfClass>
<typeOfReportingPerson>CO</typeOfReportingPerson>
</reportingPersonInfo>
<reportingPersonInfo>
<reportingPersonCIK>0001621607</reportingPersonCIK>
<reportingPersonName>Viking Long Fund GP LLC</reportingPersonName>
<memberOfGroup>b</memberOfGroup>
<fundType>OO</fundType>
<citizenshipOrOrganization>DE</citizenshipOrOrganization>
<soleVotingPower>0</soleVotingPower>
<sharedVotingPower>194184</sharedVotingPower>
<soleDispositivePower>0</soleDispositivePower>
<sharedDispositivePower>194184</sharedDispositivePower>
<aggregateAmountOwned>194184</aggregateAmountOwned>
<isAggregateExcludeShares>N</isAggregateExcludeShares>
<percentOfClass>0.1</percentOfClass>
<typeOfReportingPerson>OO</typeOfReportingPerson>
</reportingPersonInfo>
<reportingPersonInfo>
<reportingPersonCIK>0001621596</reportingPersonCIK>
<reportingPersonName>Viking Long Fund Master Ltd.</reportingPersonName>
<memberOfGroup>b</memberOfGroup>
<fundType>OO</fundType>
<citizenshipOrOrganization>E9</citizenshipOrOrganization>
<soleVotingPower>0</soleVotingPower>
<sharedVotingPower>194184</sharedVotingPower>
<soleDispositivePower>0</soleDispositivePower>
<sharedDispositivePower>194184</sharedDispositivePower>
<aggregateAmountOwned>194184</aggregateAmountOwned>
<isAggregateExcludeShares>N</isAggregateExcludeShares>
<percentOfClass>0.1</percentOfClass>
<typeOfReportingPerson>CO</typeOfReportingPerson>
</reportingPersonInfo>
<reportingPersonInfo>
<reportingPersonCIK>0001886738</reportingPersonCIK>
<reportingPersonName>Viking Global Opportunities Parent GP LLC</reportingPersonName>
<memberOfGroup>b</memberOfGroup>
<fundType>OO</fundType>
<citizenshipOrOrganization>DE</citizenshipOrOrganization>
<soleVotingPower>0</soleVotingPower>
<sharedVotingPower>21373290</sharedVotingPower>
<soleDispositivePower>0</soleDispositivePower>
<sharedDispositivePower>21373290</sharedDispositivePower>
<aggregateAmountOwned>21373290</aggregateAmountOwned>
<isAggregateExcludeShares>N</isAggregateExcludeShares>
<percentOfClass>11.3</percentOfClass>
<typeOfReportingPerson>OO</typeOfReportingPerson>
</reportingPersonInfo>
<reportingPersonInfo>
<reportingPersonCIK>0001629476</reportingPersonCIK>
<reportingPersonName>Viking Global Opportunities GP LLC</reportingPersonName>
<memberOfGroup>b</memberOfGroup>
<fundType>OO</fundType>
<citizenshipOrOrganization>DE</citizenshipOrOrganization>
<soleVotingPower>0</soleVotingPower>
<sharedVotingPower>21373290</sharedVotingPower>
<soleDispositivePower>0</soleDispositivePower>
<sharedDispositivePower>21373290</sharedDispositivePower>
<aggregateAmountOwned>21373290</aggregateAmountOwned>
<isAggregateExcludeShares>N</isAggregateExcludeShares>
<percentOfClass>11.3</percentOfClass>
<typeOfReportingPerson>OO</typeOfReportingPerson>
</reportingPersonInfo>
<reportingPersonInfo>
<reportingPersonCIK>0001629472</reportingPersonCIK>
<reportingPersonName>Viking Global Opportunities Portfolio GP LLC</reportingPersonName>
<memberOfGroup>b</memberOfGroup>
<fundType>OO</fundType>
<citizenshipOrOrganization>DE</citizenshipOrOrganization>
<soleVotingPower>0</soleVotingPower>
<sharedVotingPower>21373290</sharedVotingPower>
<soleDispositivePower>0</soleDispositivePower>
<sharedDispositivePower>21373290</sharedDispositivePower>
<aggregateAmountOwned>21373290</aggregateAmountOwned>
<isAggregateExcludeShares>N</isAggregateExcludeShares>
<percentOfClass>11.3</percentOfClass>
<typeOfReportingPerson>OO</typeOfReportingPerson>
</reportingPersonInfo>
<reportingPersonInfo>
<reportingPersonCIK>0001629482</reportingPersonCIK>
<reportingPersonName>Viking Global Opportunities Illiquid Investments Sub-Master LP</reportingPersonName>
<memberOfGroup>b</memberOfGroup>
<fundType>OO</fundType>
<citizenshipOrOrganization>E9</citizenshipOrOrganization>
<soleVotingPower>0</soleVotingPower>
<sharedVotingPower>21373290</sharedVotingPower>
<soleDispositivePower>0</soleDispositivePower>
<sharedDispositivePower>21373290</sharedDispositivePower>
<aggregateAmountOwned>21373290</aggregateAmountOwned>
<isAggregateExcludeShares>N</isAggregateExcludeShares>
<percentOfClass>11.3</percentOfClass>
<typeOfReportingPerson>PN</typeOfReportingPerson>
</reportingPersonInfo>
<reportingPersonInfo>
<reportingPersonCIK>0001133006</reportingPersonCIK>
<reportingPersonName>HALVORSEN OLE ANDREAS</reportingPersonName>
<memberOfGroup>b</memberOfGroup>
<fundType>OO</fundType>
<citizenshipOrOrganization>Q8</citizenshipOrOrganization>
<soleVotingPower>0</soleVotingPower>
<sharedVotingPower>22055375</sharedVotingPower>
<soleDispositivePower>0</soleDispositivePower>
<sharedDispositivePower>22055375</sharedDispositivePower>
<aggregateAmountOwned>22055375</aggregateAmountOwned>
<isAggregateExcludeShares>N</isAggregateExcludeShares>
<percentOfClass>11.7</percentOfClass>
<typeOfReportingPerson>IN</typeOfReportingPerson>
</reportingPersonInfo>
<reportingPersonInfo>
<reportingPersonCIK>0001621842</reportingPersonCIK>
<reportingPersonName>Ott David C.</reportingPersonName>
<memberOfGroup>b</memberOfGroup>
<fundType>OO</fundType>
<citizenshipOrOrganization>X1</citizenshipOrOrganization>
<soleVotingPower>0</soleVotingPower>
<sharedVotingPower>22055375</sharedVotingPower>
<soleDispositivePower>0</soleDispositivePower>
<sharedDispositivePower>22055375</sharedDispositivePower>
<aggregateAmountOwned>22055375</aggregateAmountOwned>
<isAggregateExcludeShares>N</isAggregateExcludeShares>
<percentOfClass>11.7</percentOfClass>
<typeOfReportingPerson>IN</typeOfReportingPerson>
</reportingPersonInfo>
<reportingPersonInfo>
<reportingPersonCIK>0001711393</reportingPersonCIK>
<reportingPersonName>Shabet Rose Sharon</reportingPersonName>
<memberOfGroup>b</memberOfGroup>
<fundType>OO</fundType>
<citizenshipOrOrganization>X1</citizenshipOrOrganization>
<soleVotingPower>0</soleVotingPower>
<sharedVotingPower>22055375</sharedVotingPower>
<soleDispositivePower>0</soleDispositivePower>
<sharedDispositivePower>22055375</sharedDispositivePower>
<aggregateAmountOwned>22055375</aggregateAmountOwned>
<isAggregateExcludeShares>N</isAggregateExcludeShares>
<percentOfClass>11.7</percentOfClass>
<typeOfReportingPerson>IN</typeOfReportingPerson>
</reportingPersonInfo>
</reportingPersons>
<items1To7>
<item1>
<securityTitle>Common Stock, par value $0.001 per share</securityTitle>
<issuerName>BridgeBio Pharma, Inc.</issuerName>
<issuerPrincipalAddress>
<com:street1>3160 Porter Drive</com:street1>
<com:street2>Suite 250</com:street2>
<com:city>Palo Alto</com:city>
<com:stateOrCountry>CA</com:stateOrCountry>
<com:zipCode>94304</com:zipCode>
</issuerPrincipalAddress>
<commentText>Pursuant to Rule 13d-2 under the Securities Exchange Act of 1934, as amended, this Amendment No. 5 to the Schedule 13D ("Amendment No. 5") amends certain items of the Schedule 13D filed with the Commission on July 8, 2019, as amended and supplemented by Amendment No. 1 filed with the Commission on July 19, 2023, Amendment No. 2 filed with the Commission on November 22, 2023, Amendment No. 3 filed with the Commission on August 20, 2024 and Amendment No. 4 filed with the Commission on November 6, 2024 (collectively, the "Schedule 13D") relating to the Common Stock, par value $0.001 per share (the "Common Stock") of BridgeBio Pharma, Inc., a Delaware corporation (the "Issuer"). All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Schedule 13D.</commentText>
</item1>
<item4>
<transactionPurpose>Item 4 of the Schedule 13D is hereby amended and supplemented as follows:&#13;
&#13;
On January 31, 2025, VGEM, VLFM and Opportunities Fund sold 143,266 shares of Common Stock, 57,020 shares of Common Stock and 2,865,330 shares of Common Stock, respectively, at a price of $34.90 per share.</transactionPurpose>
</item4>
<item5>
<percentageOfClassSecurities>Item 5(a) of the Schedule 13D is hereby amended and supplemented as follows:&#13;
&#13;
The information contained on each of the cover pages of this Amendment No. 5 and the information set forth or incorporated in Items 2, 3, 4 and 6 of the Schedule 13D are hereby incorporated herein by reference.&#13;
&#13;
VGEM has the authority to dispose of and vote the shares of Common Stock directly owned by it, which power may be exercised by its investment manager, VGP, and by VGI, an affiliate of VGP, which provides managerial services to VGEM. Viking Global Equities LP (a Delaware limited partnership) and Viking Global Equities III Ltd. (a Cayman Islands exempted company), through its investment in VGE III Portfolio Ltd. (a Cayman Islands exempted company), invest substantially all of their assets through VGEM.&#13;
&#13;
VLFM has the authority to dispose of and vote the shares of Common Stock directly owned by it, which power may be exercised by its investment manager, VLFGP, and by VGI, an affiliate of VLFGP, which provides managerial services to VLFM. Viking Long Fund LP (a Delaware limited partnership) and Viking Long Fund III Ltd. (a Cayman Islands exempted company), through its investment in Viking Long Fund Intermediate L.P. (a Cayman Islands limited partnership), invest substantially all of their assets through VLFM.&#13;
&#13;
Opportunities Fund has the authority to dispose of and vote the shares of Common Stock directly owned by it, which power may be exercised by its general partner, Opportunities Portfolio GP, and by VGI, an affiliate of Opportunities Portfolio GP, which provides managerial services to Opportunities Fund. Viking Global Opportunities LP (a Delaware limited partnership) and Viking Global Opportunities III LP (a Cayman Islands exempted limited partnership), through its investment in Viking Global Opportunities Intermediate LP (a Cayman Islands exempted limited partnership), invest substantially all of their assets in Viking Global Opportunities Master LP (a Cayman Islands exempted limited partnership), which in turn invests through Opportunities Fund.&#13;
&#13;
VGI provides managerial services to the Funds. VGI has the power to direct the vote and disposition of the shares of Common Stock directly held by the Funds. Accordingly, VGI may be deemed to have beneficial ownership over any shares of Common Stock directly owned by the Funds.&#13;
&#13;
VGP serves as investment manager to VGEM and has the power to direct the vote and disposition of the shares of Common Stock directly held by VGEM. Accordingly, VGP may be deemed to have beneficial ownership over any shares of Common Stock directly owned by VGEM.&#13;
&#13;
VLFGP serves as the investment manager of VLFM and has the power to direct the vote and disposition of the shares of Common Stock directly held by VLFM. Accordingly, VLFGP may be deemed to have beneficial ownership over any shares of Common Stock directly owned by VLFM.&#13;
&#13;
Opportunities Portfolio GP serves as the general partner of Opportunities Fund and has the power to direct the vote and disposition of the shares of Common Stock directly held by Opportunities Fund. Accordingly, Opportunities Portfolio GP may be deemed to have beneficial ownership over any shares of Common Stock directly owned by Opportunities Fund.&#13;
&#13;
Opportunities GP serves as the sole member of Opportunities Portfolio GP and has the power to direct the vote and disposition of the shares of Common Stock controlled by Opportunities Portfolio GP, which consists of the shares of Common Stock directly held by Opportunities Fund. Accordingly, Opportunities GP may be deemed to have beneficial ownership over any shares of Common Stock deemed beneficially owned by Opportunities Portfolio GP, consisting of any shares of Common Stock directly owned by Opportunities Fund.&#13;
&#13;
Opportunities Parent serves as the sole member of Opportunities GP, which has the power to direct the vote and disposition of the shares of Common Stock controlled by Opportunities Portfolio GP, which consists of the shares of Common Stock directly held by Opportunities Fund. Accordingly, Opportunities Parent may be deemed to have beneficial ownership over any shares of Common Stock deemed beneficially owned by Opportunities GP, consisting of any shares of Common Stock directly owned by Opportunities Fund.&#13;
&#13;
Messrs. Halvorsen and Ott and Ms. Shabet, as Executive Committee Members of Viking Global Partners LLC (the general partner of VGI), VGP, VLFGP and Opportunities Parent, have shared authority to direct the voting and disposition of the shares of Common Stock beneficially owned by VGI, VGP, VLFGP and Opportunities Parent. Accordingly, each of Messrs. Halvorsen and Ott and Ms. Shabet may be deemed to have beneficial ownership over any shares of Common Stock deemed beneficially owned by VGI, VGP, VLFGP and Opportunities Parent.&#13;
&#13;
Except as disclosed in this Amendment No. 5, none of the Reporting Persons beneficially owns any shares of Common Stock or has the right to acquire any shares of Common Stock.&#13;
&#13;
Except as disclosed in this Amendment No. 5, none of the Reporting Persons presently has the power to vote or to direct the vote or to dispose or direct the disposition of any shares of Common Stock that such Reporting Person may be deemed to beneficially own.</percentageOfClassSecurities>
<numberOfShares>Item 5(b) of the Schedule 13D is hereby amended and supplemented as follows:&#13;
&#13;
The information contained on each of the cover pages of the Schedule 13D and the information set forth or incorporated in Items 2, 3, 4 and 6 of the Schedule 13D are hereby incorporated herein by reference.&#13;
&#13;
The percentage of outstanding shares of Common Stock that may be deemed to be beneficially owned by each Reporting Person is set forth on Line 13 of such Reporting Person's cover sheet. Such percentage was calculated for each Reporting Person based on 188,989,802 shares of Common Stock outstanding as of November 5, 2024, as reported in the Issuer's quarterly report on Form 10-Q filed with the Commission on November 12, 2024.</numberOfShares>
<transactionDesc>Item 5(c) of the Schedule 13D is hereby amended and supplemented as follows:&#13;
&#13;
The response to Item 4 of this Amendment No. 5 is incorporated by reference herein. Other than as disclosed in this Amendment No. 5, the Reporting Persons have not effected any transactions in the Common Stock during the past 60 days.</transactionDesc>
</item5>
</items1To7>
<signatureInfo>
<signaturePerson>
<signatureReportingPerson>VIKING GLOBAL INVESTORS LP</signatureReportingPerson>
<signatureDetails>
<signature>/s/ Scott M. Hendler</signature>
<title>Scott M. Hendler on behalf of VIKING GLOBAL INVESTORS LP (1)(2)(3)</title>
<date>01/31/2025</date>
</signatureDetails>
</signaturePerson>
<signaturePerson>
<signatureReportingPerson>VIKING GLOBAL PERFORMANCE LLC</signatureReportingPerson>
<signatureDetails>
<signature>/s/ Scott M. Hendler</signature>
<title>Scott M. Hendler on behalf of VIKING GLOBAL PERFORMANCE LLC (1)(2)(3)</title>
<date>01/31/2025</date>
</signatureDetails>
</signaturePerson>
<signaturePerson>
<signatureReportingPerson>Viking Global Equities Master Ltd.</signatureReportingPerson>
<signatureDetails>
<signature>/s/ Scott M. Hendler</signature>
<title>Scott M. Hendler on behalf of Viking Global Equities Master Ltd. (1)(2)(3)</title>
<date>01/31/2025</date>
</signatureDetails>
</signaturePerson>
<signaturePerson>
<signatureReportingPerson>Viking Long Fund GP LLC</signatureReportingPerson>
<signatureDetails>
<signature>/s/ Scott M. Hendler</signature>
<title>Scott M. Hendler on behalf of Viking Long Fund GP LLC (1)(2)(3)</title>
<date>01/31/2025</date>
</signatureDetails>
</signaturePerson>
<signaturePerson>
<signatureReportingPerson>Viking Long Fund Master Ltd.</signatureReportingPerson>
<signatureDetails>
<signature>/s/ Scott M. Hendler</signature>
<title>Scott M. Hendler on behalf of Viking Long Fund Master Ltd. (1)(2)(3)</title>
<date>01/31/2025</date>
</signatureDetails>
</signaturePerson>
<signaturePerson>
<signatureReportingPerson>Viking Global Opportunities Parent GP LLC</signatureReportingPerson>
<signatureDetails>
<signature>/s/ Scott M. Hendler</signature>
<title>Scott M. Hendler on behalf of Viking Global Opportunities Parent GP LLC (1)(2)(3)</title>
<date>01/31/2025</date>
</signatureDetails>
</signaturePerson>
<signaturePerson>
<signatureReportingPerson>Viking Global Opportunities GP LLC</signatureReportingPerson>
<signatureDetails>
<signature>/s/ Scott M. Hendler</signature>
<title>Scott M. Hendler on behalf of Viking Global Opportunities GP LLC (1)(2)(3)</title>
<date>01/31/2025</date>
</signatureDetails>
</signaturePerson>
<signaturePerson>
<signatureReportingPerson>Viking Global Opportunities Portfolio GP LLC</signatureReportingPerson>
<signatureDetails>
<signature>/s/ Scott M. Hendler</signature>
<title>Scott M. Hendler on behalf of Viking Global Opportunities Portfolio GP LLC (1)(2)(3)</title>
<date>01/31/2025</date>
</signatureDetails>
</signaturePerson>
<signaturePerson>
<signatureReportingPerson>Viking Global Opportunities Illiquid Investments Sub-Master LP</signatureReportingPerson>
<signatureDetails>
<signature>/s/ Scott M. Hendler</signature>
<title>Scott M. Hendler on behalf of Viking Global Opportunities Illiquid Investments Sub-Master LP (1)(2)(3)</title>
<date>01/31/2025</date>
</signatureDetails>
</signaturePerson>
<signaturePerson>
<signatureReportingPerson>HALVORSEN OLE ANDREAS</signatureReportingPerson>
<signatureDetails>
<signature>/s/ Scott M. Hendler</signature>
<title>Scott M. Hendler on behalf of HALVORSEN OLE ANDREAS (1)</title>
<date>01/31/2025</date>
</signatureDetails>
</signaturePerson>
<signaturePerson>
<signatureReportingPerson>Ott David C.</signatureReportingPerson>
<signatureDetails>
<signature>/s/ Scott M. Hendler</signature>
<title>Scott M. Hendler on behalf of Ott David C. (2)</title>
<date>01/31/2025</date>
</signatureDetails>
</signaturePerson>
<signaturePerson>
<signatureReportingPerson>Shabet Rose Sharon</signatureReportingPerson>
<signatureDetails>
<signature>/s/ Scott M. Hendler</signature>
<title>Scott M. Hendler on behalf of Shabet Rose Sharon (3)</title>
<date>01/31/2025</date>
</signatureDetails>
</signaturePerson>
<commentText>(1) Scott M. Hendler is signing on behalf of O. Andreas Halvorsen, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL PERFORMANCE LLC, on behalf of itself and VIKING GLOBAL EQUITIES MASTER LTD., and as an Executive Committee Member of VIKING LONG FUND GP LLC, on behalf of itself and VIKING LONG FUND MASTER LTD., and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, and VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737).&#13;
&#13;
&#13;
(2) Scott M. Hendler is signing on behalf of David C. Ott, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL PERFORMANCE LLC, on behalf of itself and VIKING GLOBAL EQUITIES MASTER LTD., and as an Executive Committee Member of VIKING LONG FUND GP LLC, on behalf of itself and VIKING LONG FUND MASTER LTD., and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, and VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Ott on February 12, 2021 (SEC File No. 005-49737).&#13;
&#13;
&#13;
(3) Scott M. Hendler is signing on behalf of Rose S. Shabet, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL PERFORMANCE LLC, on behalf of itself and VIKING GLOBAL EQUITIES MASTER LTD., and as an Executive Committee Member of VIKING LONG FUND GP LLC, on behalf of itself and VIKING LONG FUND MASTER LTD., and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, and VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Ms. Shabet on February 12, 2021 (SEC File No. 005-49737).</commentText>
</signatureInfo>
</formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
